
The total number of cases in the GLP-1 MDL grew to 1,443.
Active case
People who use Ozempic® for long periods may risk health problems, including intestinal blockages and stomach paralysis (gastroparesis).
Connect with an attorneyActive case
The number of people filing Ozempic lawsuits increased by nearly 12 times from July to November 2024. The plaintiffs allege that drugmaker Novo Nordisk failed to warn them that the medication can cause severe gastroparesis, intestinal blockages, vision loss and death. The first Ozempic lawsuits were filed in August 2023, and lawsuits continue to be filed today.
Jump link to timeline section: Explore the full timeline of Ozempic litigation.
People are filing Ozempic lawsuits alleging they developed unexpected and severe side effects from the drug, which is also called semaglutide. Injuries include gastroparesis and other gastrointestinal injuries. Ozempic’s warning label didn’t include these possible side effects. Lawyers filed a motion to consolidate these lawsuits into multidistrict litigation (MDL) in December 2023.
The Ozempic MDL is titled In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094. MDL is a court procedure used to streamline multiple individual cases with common defendants and facts into one docket for pretrial purposes. This can help the court be more efficient. The captioned name doesn’t have Ozempic in it because the MDL encompasses several drugs approved for the treatment of diabetes and weight management, including Ozempic, that are medically classed as glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
The Ozempic MDL was established in February 2024 in the Eastern District of Pennsylvania. U.S. District Judge Karen Marston is the presiding judge. As of February 3, 2025, there were 1,443 pending actions in the MDL.
The other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) drugs involved in the MDL lawsuits currently include Wegovy®, Rybelsus®, Mounjaro® and Trulicity®.
The lawsuits are against drug manufacturers Novo Nordisk and Eli Lilly. Novo Nordisk is the maker of Ozempic, Wegovy and Rybelsus. Eli Lilly manufactures Mounjaro and Trulicity.
These highly publicized lawsuits may open the door for other people harmed by Ozempic and similar drugs.
Many other people have filed similar lawsuits after developing unexpected semaglutide side effects. These lawsuits allege several similar facts:
If you or a loved one were harmed by Ozempic (or any other diabetes drug), you may have a case. Connect with a GLP-1 RA attorney to determine your eligibility for an Ozempic lawsuit.
Contact us
Complete this form or call 1.800.768.4026 to contact attorney Sara Couch for more information or to discuss a potential Ozempic claim.
No class action lawsuits have been filed against Ozempic. So far, hundreds of individual lawsuits have been consolidated in a federal MDL in Pennsylvania, but MDLs and class action lawsuits are very different.
The Ozempic MDL also includes cases involving other GLP-1 prescription medicines. Those include Rybelsus and Wegovy (manufactured by defendant Novo Nordisk), and Trulicity and Mounjaro (manufactured by Eli Lilly and Co.).
Class action lawsuits are filed by a group of individuals against a party that allegedly harmed them. This group is known as a “class.” The class represents the interests of a larger group of people with similar injuries and claims.
Let’s say Company A leaked personal data for thousands of people. John and Jane Doe might be able to file a class action lawsuit against Company A representing the other thousands of people. Every person whose data was leaked does not need to file a lawsuit because they were all wronged by the same party in the same way and at the same time. If they win a trial or settle with the defendant, the court will notify the “class” and distribute the funds between them.
Unlike a class action lawsuit, people with a lawsuit in an MDL have an individual case. If their individual case goes to trial and the case is decided in favor of the injured party (plaintiff), the MDL lawsuit award in that specific case goes only to that individual. Importantly, individuals retain their own lawyers, have their own rights of recovery and have their own burden of proof.
Ozempic lawsuit payout amounts are unknown because there are no payouts, verdicts, settlements or awards yet. All semaglutide matters are still in the beginning stages of litigation. As the litigation progresses, award amounts may be decided and made public. At some point, defendants may agree to settlement awards to plaintiffs, which individuals can choose to accept or deny in favor of going to trial.
The plaintiff is the person filing the lawsuit. In this MDL, the plaintiff is the individual harmed by the prescription medicine they took. People who have been harmed by GLP-1 RA class drugs and filed lawsuits include:
These are just a few examples of the thousands of people who have reported severe Ozempic side effects and the hundreds of people who have filed lawsuits. If you believe you were harmed by this drug, an Ozempic attorney may be able to help.
Ozempic litigation is new and evolving. The first lawsuits were filed in 2023 and continue to progress through the court system. See a full Ozempic lawsuit update timeline.
Ozempic is an injectable medication approved for treating type 2 diabetes. It is manufactured by Novo Nordisk. It has become popular for off-label use as a weight-loss aid. Officially, Ozempic is approved by the U.S. Food and Drug Administration (FDA) to lower blood sugar levels and reduce the risk of heart attack, stroke or death in adults with type 2 diabetes. It is also known by its generic name, semaglutide. Semaglutide medications work by:
These functions help balance blood sugar in diabetic patients. In non-diabetic patients, they can restrict appetite and lead to weight loss. Other notable semaglutide drugs include Rybelsus® and Wegovy®.
Novo Nordisk created Ozempic after years of testing and developing GLP-1 drugs. Ozempic was approved for type 2 diabetes in 2017, but its origins at Novo Nordisk stretch back nearly a decade earlier.
The first GLP-1 agonist was exenatide, approved for U.S. use in 2005. It was marketed as Byetta (produced by Eli Lilly & Amylin Pharmaceuticals). Byetta was successful at moderating blood sugar levels but had to be injected twice a day.
Other pharmaceutical companies began developing their own GLP-1 drugs to improve upon Byetta. Novo Nordisk discovered liraglutide, another GLP-1 receptor agonist. In 2010, it received approval for the drug as a type 2 diabetes treatment and called it Victoza.
Novo Nordisk researchers noticed that rats injected with liraglutide began to fast, nearly starving themselves. Humans responded similarly. Researchers found that people on an intravenous drip of liraglutide ate 12% less at a lunch buffet, compared to people receiving a placebo.
The company began to study GLP-1s for both diabetes and weight loss. Its second liraglutide formulation, Saxenda, was FDA-approved for weight loss in 2014. But Saxenda had drawbacks. It only led to modest weight loss and had to be injected daily. So Novo Nordisk went back to the drawing board and created semaglutide.
It was approved for type 2 diabetes in 2017 as Ozempic. In 2021, it was approved for chronic weight management as Wegovy.
Ozempic works by signaling your brain that you’re full. It does this by mimicking a natural hormone in your body.
Novo Nordisk claims that Ozempic helps your pancreas produce insulin so blood sugar levels lower, preventing your liver from producing and releasing too much sugar into your body and slowing down food before it can leave your stomach. However, no one knows specifically how it does this.
Ozempic falls into a group of drugs known as GLP-1 receptor agonists (GLP-1 RAs). These drugs use peptides that mimic natural satiety hormones in our bodies. Semaglutide is one of these peptides. Other GLP-1 RAs may use different peptides, such as liraglutide or tirzepatide.
For non-medical professionals, medical jargon can be difficult to keep straight. Here’s a quick term glossary.
By mimicking these hormones, the drug can help regulate appetite, food intake, insulin release and blood sugar levels.
According to the FDA, the medication dose should be gradually increased weekly. Patients are expected to take the drug long term. According to some research, taking the drug long term may increase the risk of side effects.
The FDA Center for Drug Evaluation and Research (CDER) evaluates new drugs before they go on the market. The evaluation process has several steps.
Ozempic is not FDA-approved to treat weight loss. This means the FDA has not evaluated evidence of the drug’s safety as a weight loss medication.
Ozempic is popular for off-label use as a weight loss drug. Off-label use of drugs is both common and legal. It allows doctors to use their judgment to treat a variety of conditions and can expand the usefulness of certain drugs. But it can lead to unexpected or unadvertised side effects.
Soon after Ozempic hit the market in 2017, Novo Nordisk began to market the drug as a potential weight loss drug. It then developed Wegovy, a higher-dose version of Ozempic, to treat weight gain and obesity. Since then, both drugs have surged in popularity for weight loss, resulting in national shortages. Ozempic revenue reached $13.9 billion in 2023.
While Ozempic has proven to work as an off-label weight loss aid, patients have reported unexpected and serious side effects and injuries including intestinal blockages and stomach paralysis or gastroparesis. For many people, Ozempic is not a safe weight loss aid.
Many patients do regain weight after they stop taking Ozempic. One study showed that patients who stopped taking Ozempic regained two-thirds of the weight they had previously lost within one year.
However, Ozempic can have serious, long-term side effects that can impact your ability to live normally. Ceasing Ozempic may be a way to help manage these side effects. If you are taking Ozempic, consult your doctor to determine if you should, or need to, stop.
Yes, other versions of Ozempic (semaglutide) are available. Novo Nordisk has two other versions: Rybelsus and Wegovy. All three versions have been linked to severe side effects. Compounded versions of semaglutide are also available.
Drug compounding is the process of mixing different medications or substances together. Compounding pharmacists may do this to tailor a drug to a specific patient’s needs. These versions of semaglutide are not FDA-approved or reviewed by the drug’s maker and can be even more dangerous.
Compounding pharmacies have begun selling unregulated versions of semaglutide. These may be attractive to patients for two reasons:
The FDA has issued warnings regarding compounded semaglutide.
Compounded semaglutide drugs may use the salt form of the hormone, including semaglutide sodium and semaglutide acetate. While similar in name, the salt forms are not the same active ingredient as the approved base version of semaglutide. The FDA has urged patients not to take these drugs because they are not safe for weight loss or any other use of Ozempic.
“Patients should be aware that some products sold as ‘semaglutide’ may not contain the same active ingredient as FDA-approved semaglutide products and may be the salt formulations. Products containing these salts, such as semaglutide sodium and semaglutide acetate, have not been shown to be safe and effective.”
- U.S. Food and Drug Administration
Experts have linked Ozempic to a variety of health risks. The drug makers don’t list many of the most serious conditions on the drug’s warning label. Health issues related to Ozempic include intestinal blockages, gastroenteritis and stomach paralysis/gastroparesis.
The FDA is currently investigating reports of these health issues filed through its FDA Adverse Event Reporting System (FAERS). FAERS allows people to report product issues directly to the agency.
FDA investigations have led to the Ozempic warning label being updated several times.
However, thousands of people were prescribed the drug before these warning label updates. Still other risks are not disclosed on the Ozempic label at all. Ozempic use has also been linked to hundreds of deaths. Death occurring after taking Ozempic may be due to a condition the drug caused or due to a pre-existing condition the drug worsened.
If you or a loved one have experienced Ozempic side effects that were not disclosed on the warning label (or were added after you started the drug), you may be eligible for an Ozempic lawsuit. Speak with an Ozempic lawyer to determine if you have a case for your unlisted side effects.
People who have experienced serious Ozempic reactions are filing lawsuits. These side effects were not listed or adequately listed by the manufacturer of Ozempic, Novo Nordisk.
A July 3, 2024 study linked Ozempic and Wegovy use to an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) for diabetic or overweight patients. NAION occurs when blood flow to the optic nerve is disturbed or cut off. This can lead to vision loss in the eye.
Breaking down the condition’s name helps to understand what is happening:
The study’s senior author, Dr. Joseph Rizzo, called NAION “in effect, a stroke of the optic nerve.” Rizzo is the director of neuro-ophthalmology at Mass Eye and Ear in Boston.
The July study analyzed:
The researchers concluded that “this study’s findings suggest an association between semaglutide and NAION.” Please contact Motley Rice Ozempic and Wegovy lawyers if you have suffered vision loss or blindness after taking Ozempic, Wegovy or semaglutide.
Studies are starting to link semaglutide drugs to other serious health issues, including blood clots that can cause deep vein thrombosis or pulmonary embolism.
A 2021 analysis of semaglutide clinical trials found an increased risk of DVTs in patients who took the drug. The analysis found semaglutide drugs like Ozempic increased the risk of DVT by 266%. Blood clots, DVT and PE are very serious side effects. Patients should discuss these risks with their doctor before beginning a semaglutide drug regimen.
Learn more about Ozempic, blood clots and related conditions.
Gallbladder disease was added to semaglutide warning labels in March 2022. In August, the FDA published an investigation into reported cases of acute cholecystitis (AC). AC is a gallbladder disease that occurs when the organ is inflamed.
The FDA investigation into AC and GLP-1 RA drugs reported:
Cholelithiasis, or gallstones, was also added to the approval label. The Ozempic warning label reports:
The updated label urges anyone who develops abdominal pain, jaundice, fever or clay-colored stools to seek a healthcare provider’s help right away.
Gastroenteritis is not on Ozempic’s warning label. However, the FDA has received dozens of reports of gastroenteritis from people taking semaglutide drugs.
Gastroenteritis can be caused by viruses, medications or chemicals. This condition is an inflammation of the stomach and intestines. Viral gastroenteritis may be known more commonly as the stomach flu and has similar symptoms to medication-caused gastroenteritis.
Symptoms include:
The vomiting and diarrhea are the largest concerns, as patients can quickly become dehydrated. Dehydration can have serious effects on the human body.
Doctors have also reported patients experiencing stomach paralysis, also called gastroparesis or delayed gastric emptying. Stomach paralysis prevents the stomach’s nerves and muscles from working properly. This results in food sitting too long in the stomach. Some patients may experience mild discomfort, while others may need hospitalization, surgery and feeding tubes to manage the condition. Common symptoms of gastroparesis include:
|
Any patients taking Ozempic (or any other GLP-1 RA) should speak with their doctor immediately if these symptoms arise.
Gastroparesis is not included on the Ozempic warning label as a risk or side effect. It is briefly mentioned in the “Drug Interactions” section to say the drug “causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.” It is also briefly mentioned in the “Pharmacodynamics” section, which describes how the drug works.
Neither of these mentions adequately discloses the severe risks of gastroparesis. They do not quantify how many patients might experience stomach paralysis or how impactful it can be on a person’s daily life. People are filing gastroparesis lawsuits after taking GLP-1 drugs that led to hospitalization for stomach paralysis.
Learn more about Ozempic and stomach paralysis.
Ileus and intestinal obstruction were not included on Ozempic’s warning label for many years. Intestinal obstructions may also be referred to as bowel obstructions.
A May 2023 letter to the editor in the research journal Acta Pharmaceutica Sinica B (APSB) discussed these issues. The letter authors urged clinicians to be aware of the adverse effects of drugs like Ozempic on the small intestine.
According to the letter, the effects have so far been insufficiently studied in clinical settings because the trials do not last long enough.
The authors found that the high occurrences of intestinal obstruction emerge 1.6 years after GLP-1 RA treatments, but that most GLP-1 RA clinical trials have not lasted for more than a year. They also cited a study of more than 25,000 subjects that found a 3.5-fold increase in intestinal obstruction rates for people who took GLP-1 RA drugs.
Other studies have also linked Ozempic to intestinal blockages. Intestinal blockage signs and symptoms may include:
Intestinal obstruction may be caused by ileus. Ileus is a condition where the intestines do not work properly. Similar to stomach paralysis, ileus occurs when the intestines stop being able to move food through the body.
In September 2023, the warning label was updated to mention ileus in the “Postmarketing Experience” section. The warning reads:
“The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC.
Gastrointestinal Disorders: Ileus”
-Ozempic warning label, as of April 2024
The warning label still does not mention the potential harms of ileus, like blockages and obstruction. Patients with intestinal blockages may need surgery to fix the problem.
Learn more about Ozempic and intestinal obstructions.
Intraoperative pulmonary aspiration occurs when patients under anesthesia choke, typically on regurgitated food. The American Society of Anesthesiologists (ASA) published a press release on the risk of aspiration to people taking Ozempic.
The press releases noted an increased risk of aspiration because semaglutide delays gastric emptying, making food sit in the stomach longer.
“We’ve received anecdotal reports that the delay in stomach emptying could be associated with an increased risk of regurgitation and aspiration of food into the airways and lungs during general anesthesia and deep sedation.”
- ASA President Michael W. Champeau, M.D., FAAP, FASA.
In November 2024, the Ozempic warning label was updated to include pulmonary aspiration during general anesthesia or deep sedation. The ASA recommends patients hold off on the weekly dose of Ozempic before undergoing surgery and disclosing their GLP-1 status to their surgeon and anesthesiologist.
Many side effects are listed on Ozempic’s label. These side effects vary from mild nausea to serious organ injuries and cancer. Patients should consult their doctor before starting to take Ozempic to learn about these side effects. Listed side effects and reactions to Ozempic include:
If you experience any of these reactions, tell your doctor. Even mild reactions should be reported and monitored.
2.04.25
The total number of cases in the GLP-1 MDL grew to 1,443.
1.03.25
The total number of cases in the GLP-1 MDL grew to 1,331.
12.01.24
Deep vein thrombosis and blood clot cases will not be included injuries in the GLP-1 RA MDL. People who experienced these injuries may still pursue these cases. Contact GLP-1 RA attorney Sara Couch or Jonathan Orent.
12.02.24
The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,300.
11.01.24
Patients who used Ozempic filed a master complaint in the sprawling multidistrict litigation centralized in the Eastern District of Pennsylvania. They accuse Novo Nordisk and Eli Lilly & Co. of failing to warn them about the risks associated with Ozempic and other similarly classed medications.
11.01.24
The FDA has updated the Ozempic label with an additional warning about an increased risk of pulmonary aspiration. The agency’s warning indicates that some Ozempic patients may experience the condition during general anesthesia or deep sedation, even when following preoperative fasting recommendations.
11.04.24
The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,221.
10.03.24
The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,090.
10.02.24
Semaglutide drugs remain on the FDA Drug Shortage Database. Manufacturers are still working to increase production to meet the demand. This could make it harder for patients who use semaglutide drugs for weight loss, weight management or diabetes management to get the medications they need.
Tirzepatide drugs were removed from the FDA Drug Shortage Database as of October 2, 2024.
09.05.24
The CEO of Novo Nordisk appeared before a U.S. Senate committee to address what the Senate believes is an overly high price for their medications, Ozempic and Wegovy. Senator Bernie Sanders argued that the manufacturer charges Americans higher prices than it charges in other countries.
09.04.24
A new plaintiff joined the GLP-1 RA medications MDL. Juanita Gantt* sued Novo Nordisk after suffering life-threatening health issues upon taking Wegovy and Ozempic.
While taking the prescription GLP-1RA medications, Gantt was hospitalized and required emergency surgery to remove a part of her large intestine. She also suffered cardiac arrest while still recovering from surgery in the hospital. Post-surgery, Gantt required an ileostomy bag to collect waste from her body.
Her lawsuit claims the drugmaker failed to warn patients about the risk of major gastrointestinal side effects.
*Motley Rice does not represent Ms. Gantt.
09.03.24
The MDL numbers published on September 3, 2024, showed that hundreds of plaintiffs filed lawsuits against GLP-1 RA drug manufacturers. The number of GLP-1 RA lawsuits had reached 869 as of this date.
08.01.24
The number of plaintiffs in the GLP-1 RA MDL rose to 346. That’s a total of 241 new lawsuits filed in one month.
08.01.24
Judge Karen Spencer Marston issued Case Management Order No. 17. The order establishes guidelines for how plaintiffs will share expenses that their attorneys incur while performing their duties for the MDL.
07.01.24
A new study linked semaglutide drugs like Ozempic to a side effect that may cause permanent vision loss and blindness. The side effect is non-arteritic anterior ischemic optic neuropathy (NAION). It refers to blood loss to the optic nerve, which can lead to visual impairments and blindness. The study researchers concluded that “this study’s findings suggest an association between semaglutide and NAION.”
07.01.24
The latest MDL numbers show four new actions were filed. This brings the total number of GLP-1 RA lawsuits to 105. Science Day has also been moved to September 4, 2024.
06.01.24
Judge Karen Marston was appointed to head the MDL after Judge Pratter’s death in May. Judge Marston faces a complex litigation with competing interests from all sides. One of her first acts as head of the MDL was to request a status conference with leadership members.
06.01.24
More actions were filed in the MDL, bringing the total actions pending to 101. Science Day is set for September 4, 2024. Science Day helps to establish facts and relationships between the drugs, current research and the plaintiff’s claims.
05.01.24
Judge Gene E.K. Pratter, who oversaw the GLP-1 RA litigation, passed away at 78. The Philadelphia Inquirer reported Judge Pratter’s death, remembering her as a longtime lawyer, professor, mentor and volunteer. Her colleagues in the Eastern District of Pennsylvania also released a statement lamenting this “tremendous loss.” Judge Pratter’s position in the GLP-1RA MDL will be taken over by another judge appointed by the Judicial Panel on Multidistrict Litigation (JPML).
05.01.24
Motley Rice attorney Jonathan Orent appointed Co-Lead Counsel and Motley Rice attorney Sara Couch appointed Chair of Marketing Discovery, Plaintiffs Executive Committee for the Ozempic Multidistrict litigation (MDL).
04.01.24
A Motley Rice lawyer and attorneys from other firms were appointed to lead Ozempic MDL. Judge Pratter appointed these attorneys to a “plaintiffs’ committee” to help guide and lead litigation.
04.01.24
More actions filed in the MDL, bringing the total actions pending to 74.
03.01.24
The first status conference in the GLP-1 RA MDL was held on March 14. The conference covered procedural details for the suits, leadership structure and establishment of facts.
02.01.24
The MDL was established in the Eastern District of Pennsylvania with U.S. District Judge Gene E.K. Pratter as the presiding judge. Louisiana cases were transferred to the Pennsylvania MDL.
01.01.24
The FDA announced it was investigating claims that GLP-1 RAs contribute to suicidal thoughts, hair loss and intraoperative pulmonary aspiration.
12.31.23
6,487 total cases, including 89 deaths.
12.01.23
Plaintiff lawyers filed a motion to consolidate nine GLP-1 lawsuits into an MDL in Louisiana.
12.01.23
Judge James Cain, Jr. denied Novo Nordisk’s motion to dismiss. Judge Cain granted the dismissal of express warranty claims but not failure to warn claims.
11.01.23
Novo Nordisk filed a motion to dismiss the Bjorklund lawsuit.
09.01.23
Ozempic’s warning label was updated to include ileus and intestinal blockages.
08.01.23
Summons were issued to Novo Nordisk and Eli Lilly for the Bjorklund case.
08.01.23
A 44-year-old woman filed one of the first Ozempic lawsuits, Bjorklund v. Novo Nordisk et al. Jaclyn Bjorklund’s case claims Ozempic and Mounjaro caused her gastroparesis.
12.31.22
3,754 total cases, including 42 deaths.
08.01.22
The FDA published an analysis of gallbladder disease reports in patients taking Ozempic.
03.01.22
Ozempic’s warning label was updated to include gallbladder disease.
12.31.21
2,784 total cases, including 32 deaths.
12.31.20
2,339 total cases, including 30 deaths.
12.31.19
1,244 total cases, including 22 deaths.
12.31.18
1,059 total cases, including 7 deaths.
12.05.17
Ozempic receives its FDA approval and goes on the market.
These are questions people often ask about Ozempic and the Ozempic lawsuit.
The most common reported Ozempic side effects are nausea, vomiting, diarrhea, abdominal pain and constipation. These adverse reactions may be precursors to more serious side effects like stomach paralysis (gastroparesis) and intestinal blockages. Some Ozempic side effects and reactions may be life-threatening.
Mounjaro is not the same as Ozempic. They have different active ingredients but belong to the same class of drugs, GLP-1 receptor agonists. Mounjaro’s active ingredient is tirzepatide and Ozempic’s is semaglutide. Both are approved for Type 2 diabetes but have gained popularity as weight loss drugs. Mounjaro is manufactured by Eli Lilly. Ozempic is manufactured by Novo Nordisk.
You may be able to file an Ozempic lawsuit if you were harmed by the drug. Attorneys with prescription drug lawsuit experience can determine if you are eligible. If you are eligible, your Ozempic attorney can help build your case, file it and litigate it. Reach out to 1.800.768.4026 to learn more about Ozempic lawsuit eligibility.
Ozempic is not 100% safe. Like all drugs, it is associated with specific side effects. However, many of the most severe Ozempic risks (gastroparesis, intestinal blockages) are not disclosed on the drug’s warning label. Many people have not been safe from serious side effects after taking Ozempic.
Our medical attorneys have represented thousands of patients seriously hurt by dangerous prescription and over-the-counter drugs. We understand that as a patient or family member, what you know about your or a loved one’s medications may be limited.
If you believe a medicine made you sick or hurt you, attorneys at our law firm have the resources needed to thoroughly investigate and:
Learn more about our medical drug experience here.
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Victoza, Zepbound, Byetta, Bydureon BCise, Adlyxin and Trulicity remain approved by the U.S. Food and Drug Administration.
Why is there a lawsuit against Ozempic?
What is Ozempic?
Ozempic for weight loss: off-label use background
Health issues related to Ozempic
Injuries named in Ozempic side effects lawsuits
Listed Ozempic side effects
Ozempic lawsuit updates timeline
Frequently asked questions (FAQs) about Ozempic
Our medical drug litigation experience
Call us or fill out our online form with the details of your potential case.
Our team reviews your information to assess your potential case.
Talk with us about next steps.